Retina

Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.

A glaucoma expert addressed the connection between systemic blood pressure, intraocular pressure, and glaucoma.

A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.

September was one of the busiest months of the year in eye care—From ESCRS to Eyecon

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

As with so many diseases, lung cancer manifests in men and women differently in type, symptoms, and prognosis.

Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.

Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.

Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.

OT Roundup returns with MOGENRY's 4-year RP data, RCA's retina care report, SYD-101's FDA hearing, and new OCU410 GA data.

Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.

Three EURETINA 2026 e-posters examine OCT/OCTA biomarkers and real-world switching to faricimab or aflibercept 8 mg in nAMD.

Francesca Cordeiro, PhD, MD, FRCOphth, explains how Detection of Apoptosing Retinal Cells (DARC) imaging predicted the speed and direction of GA growth and could help stratify patients for treatment.

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

Sharon Fekrat, MD, FACS, FASRS, discusses how retinal imaging fits into the diagnostic picture for CVI, TBI, and neurodegenerative disease.

An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.

Topline data from the phase 2/3 study show that both dose levels of the subretinal gene therapy produced significant gains in low luminance visual acuity versus untreated control at 12 months.

Anat Loewenstein, MD, previews EURETINA 2026 Vienna: the Innovation Spotlight, 17 sessions, symposia, and more.

OT Roundup debuts with new ADHD ocular findings, a surgeon's own trifocal IOL journey, MOGENRY's FDA filing, and myopia policy news.

Alessandro Arrigo, MD, previews an ESCRS 2026 presentation on a patent-pending method that adapts blue light autofluorescence confocal imaging to grade cataracts objectively. The approach yielded reproducible numeric indices that correlated with both expert LOCS III scores and measurable loss of retinal image quality.

Q3 2026 delivered advances in some closely watched pipeline products.

Opus Genetics announced positive 3- and 6-month results OPGx-BEST1 in BEST1-related retinal diseases.

Women are more often affected than men, and the disease manifests differently between the sexes.

Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.